ALD1613
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH) . ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels[1].
Product Specifications
UNSPSC
12352203
Target
Melanocortin Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Smiles
[ALD1613]
References & Citations
[1]Andrew L Feldhaus, et al. ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology. Endocrinology. 2017 Jan 1;158 (1) :1-8.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400158-100 1x 100 µL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041073-500 1x 500 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details